Asian equity benchmarks are trading in green on Tuesday, as the market sentiments boosted followed by the positive results from trials of experimental COVID-19 vaccines offsetting worries about the rise in coronavirus cases worldwide. Pfizer and BioNTech SE announced early positive data on their joint coronavirus vaccine candidate from a German phase 1/2 covid-19 vaccine study. Moreover, firm trend in US stocks overnight and hopes for more dovish measures in the US and Europe also boosted investor sentiment. Japan's Nikkei is advancing despite stronger yen. Among the Asian markets, Japan, Singapore, Taiwan, South Korea, Indonesia, Hong Kong, China and Malaysia are in positive note.
Nikkei 225 up by 190.38 points, 0.84% to 22,907.86, Straits Times enlarged by 13.55 points or 0.52% to 2,629.85, Hang Seng rose by 442.67 points or 1.77% 25,500.66, Taiwan Weighted added 251.52 points or 2.07% to 12,426.06, KOSPI Index lifted by 32.61 points or 1.48% to 2,230.81, Jakarta Composite widened by 51.06 points, 1.01% to 5,102.17, Shanghai buoyed 3.98 points or 0.12% to 3,318.13 and FTSE Bursa Malaysia KLCI higher 9.35 points or 0.59% to 1,598.80.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: